Other equities research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of TherapeuticsMD from a sell rating to a hold rating in a report on Saturday, August 25th. ValuEngine lowered shares of TherapeuticsMD from a buy rating to a hold rating in a report on Saturday, July 28th. BidaskClub lowered shares of TherapeuticsMD from a hold rating to a sell rating in a report on Tuesday, July 3rd. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the stock a buy rating in a report on Monday, August 13th. Finally, JPMorgan Chase & Co. set a $11.00 price objective on shares of TherapeuticsMD and gave the stock a buy rating in a report on Wednesday, August 15th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $13.88.
TXMD opened at $4.89 on Monday. The company has a current ratio of 7.88, a quick ratio of 7.79 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -13.22 and a beta of 1.40. TherapeuticsMD has a twelve month low of $4.30 and a twelve month high of $7.66.
In related news, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction on Friday, October 26th. The shares were sold at an average price of $5.28, for a total value of $971,520.00. Following the completion of the transaction, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $97,603,751.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Brian Bernick sold 91,400 shares of the firm’s stock in a transaction on Friday, October 5th. The shares were sold at an average price of $5.93, for a total transaction of $542,002.00. Following the completion of the transaction, the director now directly owns 242,000 shares of the company’s stock, valued at approximately $1,435,060. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,158,800 shares of company stock worth $12,946,562. 22.85% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in TXMD. Public Employees Retirement Association of Colorado grew its position in TherapeuticsMD by 2,545.7% in the second quarter. Public Employees Retirement Association of Colorado now owns 1,071,500 shares of the company’s stock valued at $6,686,000 after purchasing an additional 1,031,000 shares in the last quarter. BlackRock Inc. grew its position in shares of TherapeuticsMD by 4.4% in the 2nd quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after acquiring an additional 608,470 shares during the period. OppenheimerFunds Inc. grew its position in shares of TherapeuticsMD by 17.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after acquiring an additional 286,123 shares during the period. Voya Investment Management LLC grew its position in shares of TherapeuticsMD by 7.7% in the 2nd quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after acquiring an additional 242,995 shares during the period. Finally, First Trust Advisors LP bought a new position in shares of TherapeuticsMD in the 3rd quarter valued at about $1,139,000. 66.13% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Featured Article: Hedge Funds – How They Work For Investors
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.